106-16-1
CAS 106-16-1
106-16-1 (CAS 106-16-1) is a pharmaceutical compound with 1 bioactivity target and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | GI50 | 4.857142857142857 ug.mL-1 | 7 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is 106-16-1 used for in pharmaceutical contexts?
106-16-1 (CAS 106-16-1) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for 106-16-1?
No adverse-event association or SIDER side-effect rows are rendered for 106-16-1 in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is 106-16-1 also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Hydroxyethyl Stearamide-MIPA with EU status "permitted".
What clinical phase is 106-16-1 in?
No phase 1-4 clinical development badge is rendered for 106-16-1 because the matched compound identifier rows do not contain a max-phase value.